摘要
目的评价TP方案(紫杉醇-顺铂)经导管动脉灌注化疗(TAI)治疗不可切除非小细胞肺癌(NSCLC)临床价值。方法随访64例行TP方案TAI治疗的不可切除NSCLC,分析预后相关因素及安全性。结果64例患者共接受172次TAI,平均每例(2.7±1.9)次。37例仅支气管动脉为肿瘤供血动脉,27例除支气管动脉外,还有肋间动脉、胸廓内动脉、胸外侧动脉、膈动脉参与供血。无严重TAI相关并发症。随访1~60个月,死亡63例。客观反应率为46.9%,疾病控制率为81.3%。全部患者肿瘤无进展的平均时间为6.7个月,中位无进展时间3个月。平均总生存时间(OS)9.8个月,中位OS6个月。6个月、12个月、24个月累积生存率分别为54.7%、29.7%、9.4%。基于单因素分析,OS的独立影响因素是TAI治疗次数和更多的肿瘤供血动脉。结论TAI是治疗不可切除NSCLC安全、有效的方法,给不可切除NSCLC患者带来了明显的临床获益,可延长患者生存时间,提高生存质量,值得临床应用与推广。
Objective To assess the clinical value of transcatheter arterial infusion(TAI)with taxolcisplatin regimen(TP regimen)in treating non-small cell lung cancer(NSCLC).Methods A total of 64 patients with unresectable NSCLC,who had received TAIwith TP regimen,were followed up,and the prognostic factors and safety were analyzed.Results A total of 172 times of TAI chemotherapy were performed in 64 patients,with a mean of(2.7±1.9)times per patient.In 37 patients,the bronchial artery was the only tumor-feeding artery.In the remaining 27 patients,in addition to the bronchial artery,the intercostal artery,internal thoracic artery,lateral thoracic artery and diaphragmatic artery also involved in the bloodsupplyto the tumors.No serious TAI-related complications occurred.The patients were followed up for 1-60 months,and 63 patients died.Objective response rate was 46.9%and disease control rate was 81.3%.The mean time of tumor progression in all patients was 6.7 months,and the median time of tumor progression was 3.0 months.The mean survival time was 9.8 months,and the median survival time was 6.0 months.The 6-month,12-month and 24-monthcumulative survival rates were 54.7%,29.7%and 9.4%respectively.Univariate analysis indicated that the number of TAI treatments and the presence of multiple tumor-feeding arteries were the independent factors influencing the total survival time.Conclusion For the treatment of unresectable NSCLC,TAI is a safe and effective method.TAI has brought significant clinical benefits to patients with unresectable NSCLC,it can prolong the survival time of patients and improve the quality of life.Therefore,this therapy is worthy of clinical application and popularization.
作者
黄坤林
刘玉金
HUANG Kunlin;LIU Yujin(Department of Oncology Intervention,Affiliated Yueyang Hospital of Integrated Traditional Chinese and Western Medicine,Shanghai University of Traditional Chinese Medicine,Shanghai 200437,China)
出处
《介入放射学杂志》
CSCD
北大核心
2020年第6期612-616,共5页
Journal of Interventional Radiology
关键词
动脉灌注化疗
肺癌
非小细胞型
紫杉醇-顺铂方案
transcatheter arterial infusion
lung cancer
non-small cell type
taxolcisplatin regimen
